In This Section

Share:

Why BBY has Pharmaxis as a Strong Buy

BBY Analyst Dr Dennis Hulme has published research today on Pharmaxis, a company that he has as a STRONG BUY.  If you would like a copy of Dr Hulme's work, please contact your BBY Adviser.  With a target price of $1.80, that's terrific upside from a current share price of $1.07.